[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645372":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":30,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":30,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":30,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":84,"whyStopped":30,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Istanbul University - Cerrahpasa","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Betamethasone Injection","ACTIVE_COMPARATOR","Participants in this arm will receive an ultrasound-guided injection of 1 ml lidocaine combined with 1 ml betamethasone at the A1 pulley level for the treatment of trigger finger.",[13],"Drug: Betamethasone",{"label":15,"type":10,"description":16,"interventionNames":17},"Dextrose Injection","Participants in this arm will receive an ultrasound-guided injection of 1 ml lidocaine combined with 1 ml 30% dextrose solution (final concentration 15%) at the A1 pulley level for the treatment of trigger finger.",[18],"Other: Dextrose Injection",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Betamethasone","Ultrasound-guided injection of 1 ml lidocaine combined with 1 ml betamethasone administered at the A1 pulley level for the treatment of trigger finger.",[9],[26],"Corticosteroid injection",{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Ultrasound-guided injection of 1 ml lidocaine combined with 1 ml 30% dextrose solution resulting in a final concentration of 15% dextrose, administered at the A1 pulley level for the treatment of trigger finger.",[15],null,[32],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},"Merve Yıldız, MD","CONTACT","+905350229993","merveyildizdr@gmail.com",[38],{"facility":39,"status":30,"city":40,"state":30,"zip":41,"country":42,"countryCode":30,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine","Istanbul","34098","Turkey (Türkiye)",{"type":44,"coordinates":45},"Point",[46,47],28.94966,41.01384,{"lat":47,"lon":46},[50,51],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},{"name":33,"role":52,"phone":30,"phoneExt":30,"email":30},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Merve Yıldız","MD","100645372","betamethasone-vs-dextrose-injections-in-trigger-finger-100645372",false,"NCT07681804","Betamethasone vs Dextrose Injections in Trigger Finger","Comparison of Ultrasound-Guided Betamethasone and Dextrose Injections in the Treatment of Trigger Finger: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Clinical diagnosis of trigger finger\n* Presence of symptoms for at least 4 weeks\n\nExclusion Criteria:\n\n* Previous surgery on the affected finger\n* Injection treatment to the affected finger within the previous 3 months\n* Active local or systemic infection\n* Active malignancy\n* Active inflammatory rheumatic disease (e.g., rheumatoid arthritis, ankylosing spondylitis, polymyalgia rheumatica, vasculitis)\n* Uncontrolled diabetes mellitus and\u002For uncontrolled hypertension\n* Autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjögren syndrome, polymyositis, dermatomyositis, adult-onset Still's disease)\n* Coagulopathy that increases the risk of injection procedures\n* Pregnancy\n* Known allergy or hypersensitivity to lidocaine, betamethasone, or dextrose\n* Mental impairment or severe psychiatric disorder that may interfere with study participation or informed consent","ALL","18 Years","75 Years",{"count":67,"type":68},42,"ESTIMATED","INTERVENTIONAL",[71],"NA","This study aims to compare the effectiveness of ultrasound-guided betamethasone and dextrose injections in patients with trigger finger.\n\nTrigger finger is a common hand condition characterized by pain, clicking, and locking of the finger due to tendon entrapment at the A1 pulley. Corticosteroid injections are widely used as a first-line treatment; however, they may be associated with potential side effects.\n\nDextrose injection is an alternative treatment that may promote tissue healing through regenerative mechanisms. However, there is limited high-quality evidence regarding its effectiveness in trigger finger.\n\nIn this randomized controlled trial, patients will be assigned to receive either betamethasone or dextrose injection under ultrasound guidance. The primary outcome will be pain intensity measured by the Numeric Rating Scale (NRS). Secondary outcomes will include triggering severity, hand function, grip and pinch strength, and fine motor skills evaluated over a 12-week follow-up period.\n\nThe results of this study may help determine whether dextrose injection is a safe and effective alternative to corticosteroid treatment in trigger finger.",[74],"Trigger Finger",[76,77,78,79,80,81,82,83],"Trigger finger","Stenosing tenosynovitis","Ultrasound-guided injection","Betamethasone injection","Dextrose injection","A1 pulley","QuickDASH","Modified Quinnell classification","NOT_YET_RECRUITING","2026-06-27",{"date":87,"type":88},"2026-07-02","ACTUAL",{"date":90,"type":68},"2026-06",{"date":92,"type":68},"2027-05",{"name":5,"class":6},1]